Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.

Official Title
-----------------
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin in Patients With Inadequate Glycemic Control on Teneligliptin)

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Teneligliptin
* Drug: Canagliflozin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women who are 20 - 75 years old HbA1c of ≥7.0% and <10.5% FPG of ≤ 270 mg/dL Patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before run-in period Exclusion Criteria: Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes Patients with serious diabetic complications Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification Patients with severe hepatic disorder or severe renal disorder.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Canagliflozin + Teneligliptin<br>Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin. | Drug: Teneligliptin<br> <br> * Other names: Tenelia, MP-513;Drug: Canagliflozin<br> <br> * Other names: Canaglu, TA-7284;|
| Placebo Comparator: Placebo + Teneligliptin<br>Patients receive placebo for 24 weeks in combination with Teneligliptin. | Drug: Teneligliptin<br> <br> * Other names: Tenelia, MP-513;Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c) | The change from baseline in percentage of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24. | Baseline, 24 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Fasting Plasma Glucose Level | The change from baseline in fasting plasma glucose level collected at Week 24. | Baseline, 24 Weeks | 
| Percentage Change in Body Weight From Baseline | The percentage change from baseline in body weight collected at Week 24. | Baseline, 24 Weeks | 
| Change From Baseline in the AUC(0-2h) for Postprandial Plasma Glucose (PPG) | The change from Baseline in AUC(0-2h) for Postprandial Plasma Glucose collected at Week 24. | 0, 0.5, 1 and 2 hour postprandial, at Baseline and 24 Weeks | 
| Change From Baseline in 2-hour Postprandial Plasma Glucose Level | The change from baseline in 2-hour postprandial plasma glucose level collected at Week 24. | 2 Hours Postprandial, at Baseline and 24 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MT-2412, MP-513, TA-7284, Teneligliptin, Canagliflozin